Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Type-specific Vaccine Virus Shedding in 2018/19 - Day 1 Post LAIV |
3 | — |
| PRIMARY Type-specific Vaccine Virus Shedding in 2018/19 - Day 2 Post LAIV |
3 | — |
| PRIMARY Type-specific Vaccine Virus Shedding in 2018/19 - Day 3 Post LAIV |
1 | — |
| PRIMARY Type-specific Vaccine Virus Shedding in 2018/19 - Day 4 Post LAIV |
3 | — |
| PRIMARY Type-specific Vaccine Virus Shedding in 2018/19 - Day 5 Post LAIV |
3 | — |
| PRIMARY Type-specific Vaccine Virus Shedding in 2018/19 - Day 6 Post LAIV |
3 | — |
| PRIMARY Type-specific Vaccine Virus Shedding in 2018/19 - Day 7 Post LAIV |
2 | — |
| PRIMARY Type-specific Vaccine Virus Shedding in 2018/19 - Day 8 Post LAIV |
2 | — |
Eligibility Criteria
Inclusion Criteria
- Children age 6 years to 15 years +364 days of age on enrolment
- Children eligible to receive LAIV in accordance with current UK vaccine policy
- Written informed consent given by parent/ guardian and assent from child
Exclusion Criteria
Contraindications to LAIV (notwithstanding allergy to egg protein), which include:
- Hypersensitivity to the active ingredients, gelatin or gentamicin (a possible trace residue)
- Previous systemic allergic reaction to LAIV
- Previous allergic reaction to an influenza vaccine (not LAIV) is a relative contra-indication, which must be discussed with the CI to confirm patient suitability
- Children/adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids*.
- Children / adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection.
- Pregnancy (determined by history). Where this cannot be confirmed, a urine pregnancy test will be performed.
- High---dose steroids is defined as a treatment course for at least one month, equivalent to a dose greater than 20mg prednisolone per day (any age), or for children under 20kg, a dose greater than 1mg/kg/day.
NB: LAIV is not contraindicated for use in individuals with asymptomatic HIV infection; or individuals who are receiving topical/inhaled/low-dose oral systemic corticosteroids or those receiving corticosteroids as replacement therapy, e.g. for adrenal insufficiency.
Data sourced from ClinicalTrials.gov (NCT03735147). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.